NewAmsterdam Pharma Company N.V.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.7M | $3.0M | $32.0K | $348.0K | $19.1M | $3.0M | $12.8M | $29.1M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $41.7M | $38.0M | $38.6M | $31.0M | $27.5M | $44.8M | $34.9M | $35.7M |
| SG&A Expense | $26.9M | $23.5M | $27.4M | $24.5M | $27.3M | $27.2M | $21.1M | $18.4M |
| Operating Income | $-64.9M | $-58.4M | $-66.0M | $-55.1M | $-35.6M | $-68.9M | $-43.2M | $-25.0M |
| Operating Margin | -1,752.6% | -1,921.7% | -206,187.5% | -15,845.7% | -186.1% | -2,314.5% | -338.5% | -85.9% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-64.1M | $-48.4M | $-74.9M | $-72.0M | $-17.4M | $-39.5M | $-92.2M | $-16.6M |
| Income Tax Expense | — | — | — | — | — | — | — | $-1.0K |
| Net Income | $-64.1M | $-48.4M | $-74.9M | $-72.0M | $-17.4M | $-39.5M | $-92.2M | $-16.6M |
| Net Margin | -1,732.9% | -1,593.5% | -234,134.4% | -20,691.1% | -90.7% | -1,327.3% | -721.7% | -57.2% |
| EPS (Basic) | $-0.52 | $-0.40 | $-0.62 | $-0.61 | $-0.15 | $-0.34 | $-0.91 | $-0.18 |
| EPS (Diluted) | $-0.52 | $-0.40 | $-0.62 | $-0.61 | $-0.15 | $-0.34 | $-0.91 | $-0.18 |
| Shares Outstanding (Basic) | 123.4M | 121.7M | 118.4M | 119.0M | 118.6M | 116.1M | 94.4M | 94.8M |
| Shares Outstanding (Diluted) | 123.4M | 121.7M | 118.4M | 119.0M | 118.6M | 116.1M | 94.4M | 94.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |